Patents Represented by Attorney Eric J. Kron
-
Patent number: 8329184Abstract: The present application discloses an improved method for conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.Type: GrantFiled: June 23, 2006Date of Patent: December 11, 2012Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Pierre Duvivier
-
Patent number: 8309096Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.Type: GrantFiled: July 15, 2009Date of Patent: November 13, 2012Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Normand Blais, Martine Boyer, Vincent Brichard, Jamila Louahed, Denis Martin, Remi Palmantier, Clement Rioux
-
Patent number: 8207123Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.Type: GrantFiled: August 20, 2010Date of Patent: June 26, 2012Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Teresa Elisa Virginia Cabezon-Silva, Jean-Pol Cassart, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
-
Patent number: 8044183Abstract: The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.Type: GrantFiled: March 12, 2010Date of Patent: October 25, 2011Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Teresa Cabezon Silva, Joseph Cohen, Moncef Mohamed Slaoui, Carlota Vinals Bassols
-
Patent number: 7811574Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal, breast, and lung cancers, autoimmune diseases, and related conditions.Type: GrantFiled: August 28, 2003Date of Patent: October 12, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Jean-Pol Cassart, Teresa Elisa Virginia Cabezon-Silva, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
-
Patent number: 7803379Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.Type: GrantFiled: December 13, 2005Date of Patent: September 28, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Teresa Elisa Virginia Cabezon-Silva, Jean-Pol Cassart, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
-
Patent number: 7439320Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung, colon, colorectal and breast cancer, are disclosed. Illustrative compositions comprise one or more Cripto tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung, colon, colorectal and breast cancer.Type: GrantFiled: August 20, 2001Date of Patent: October 21, 2008Assignee: GlaxoSmith Kline Biologicals s.a.Inventors: Jean-Pol Cassart, Thierry Coche, Remi M Palmantier, Carlota Vinals Y De Bassols
-
Patent number: 7252308Abstract: A connector for forming a sterile connection between two tubes, comprising first and second parts which comprise connectable conduits and which can mate, first and second covers which can be removed from the so-mated parts to expose connectable ends of the first and second conduits, so that the conduits can then be connected.Type: GrantFiled: November 12, 2002Date of Patent: August 7, 2007Assignee: GlaxoSmithKline Biologicals s.a.Inventor: Jacques Thilly
-
Patent number: 7241579Abstract: Methods of screening for ligands of the GPR40 receptor are provided, including methods utilizing fatty acid GPR40 ligands.Type: GrantFiled: December 18, 2001Date of Patent: July 10, 2007Assignees: SmithKline Beecham Corporation, SmithKline Beecham P.L.C.Inventors: John Leon Andrews, Celia Patricia Briscoe, Diane Michele Ignar, Allison Isobel Muir, Howard Ray Sauls, Jr., Mohammad Tadayyon
-
Patent number: 7238778Abstract: A method of modifying a test nuclear receptor (NR) polypeptide is disclosed. The method provides a test NR polypeptide sequence having a characteristic that is targeted for modification; aligning the test NR polypeptide sequence with at least one reference NR polypeptide sequence for which an X-ray structure is available; building a three-dimensional model for the test NR polypeptide using the three-dimensional coordinates of the X-ray structure(s) of at least one reference polypeptide and its sequence alignment with the test NR polypeptide sequence; examining the three-dimensional model of the test NR polypeptide sequence for characteristic differences with the reference polypeptide; and mutating at least one amino acid residue in the test NR polypeptide sequence at a characteristic difference, whereby the test NR polypeptide is modified.Type: GrantFiled: July 17, 2002Date of Patent: July 3, 2007Assignee: SmithKline Beecham CorporationInventors: Christopher J. Apolito, Randy K. Bledsoe, Millard H. Lambert, III, David D. McKee, Valerie Gail Montana, Kenneth H. Pearce, Thomas B. Stanley, Huaqiang Eric Xu, Christopher J Delves